---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-029846"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:48:45.575124+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Protalix reports FY2025 results; EC approves Elfabrio E4W regimen triggering $25M milestone

## Summary
- EC approved Elfabrio 2mg/kg every-4-weeks dosing for stable adults with Fabry in EU; $25M milestone from Chiesi triggered.
- Total 2026 revenue guided to $78M-$83M including milestone; Elfabrio sales $33-35M, Elelyso $20-23M.
- Phase 2 RELEASE trial for PRX-115 (uncontrolled gout) actively enrolling; top-line data expected H2 2027.
- Company expects cash balance ~$50M by April 2026 with no outstanding debt or warrants.
- No specific FY2025 financial numbers disclosed in the press release; focus on business and regulatory milestones.

## SEC filing metadata
- accession: 0001104659-26-029846
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/0001104659-26-029846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-029846
- JSON: https://secwatch.observer/filing/0001104659-26-029846.json
- Plain text: https://secwatch.observer/filing/0001104659-26-029846.txt

## Key facts
- Earnings Releases
  Protalix BioTherapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.
  - Period: the fiscal year ended December 31, 2025
  - Result: reported results
  source text: On March 18, 2026, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2025 and provided a business and clinical update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/0001104659-26-029846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.